SCHEMBL6409442

SCHEMBL6409442

CC(=O)c1cccc(C(N(CCCc2ccccc2)C(=O)OC(C)(C)C)S(N)(=O)=O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.39
CASR P41180 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
F2 P00734 4/20 0.36
PRSS1 P07477 4/20 0.36
PRSS2 P07478 4/20 0.36
PRSS3 P35030 4/20 0.36
BACE1 P56817 4/20 0.36
F10 P00742 2/20 0.36
MAOB P27338 1/20 0.35
GLI1 P08151 1/20 0.35
GLI2 P10070 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
PLG P00747 1/20 0.35
PLAT P00750 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7257821 0.83 L3MBTL1 (0.39) L3MBTL1
SCHEMBL6403166 0.83 L3MBTL1 (0.39) L3MBTL1
SCHEMBL6403036 0.83 CACNA1H (0.37) CASRBACE1F10MAOBGLI1
SCHEMBL6404630 0.82 L3MBTL1 (0.44) MEN1ALDH1A1KMT2AL3MBTL1
SCHEMBL7258293 0.82 L3MBTL1 (0.44) MEN1ALDH1A1KMT2AL3MBTL1
SCHEMBL22327659 0.75 L3MBTL1 (0.43) MEN1LMNAKMT2AL3MBTL1
SCHEMBL6401370 0.73 L3MBTL1 (0.40) MEN1ALDH1A1KMT2APTGDR2L3MBTL1
SCHEMBL6409447 0.72 ALDH1A1 (0.45) CASRMEN1ALDH1A1LMNAMAPT
SCHEMBL6401744 0.71 LMNA (0.38) LMNABACE1CA1
SCHEMBL17623507 0.71 OPRK1 (0.44) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900237-B2 Sulfonamide compounds as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-05-31 US disclosed
US-20030158231-A1 Sulfonamide compounds as protease inhibitors Celera Corporation 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158231-A1 Sulfonamide compounds as protease inhibitors PRSS1, PRSS3, SPINT2 SLC7A5 1631/4885CASR 1067/4885MEN1 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.